SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending following FDA approval of YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children. This landmark decision is driving widespread community discussion about its de-risking impact, significant revenue potential, and possible short squeeze, with many speculating on substantial price targets and a potential buyout by a larger pharmaceutical entity.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending as a potentially undervalued infrastructure play, with its compliance-first architecture and impressive throughput of over 11 million transactions per second positioning it as critical global financial plumbing. The community is actively discussing its live integration with Bridge, a Stripe-owned fiat anchor, enabling seamless transfers between traditional banking and crypto for institutional flows. This makes KTA an early-stage opportunity for those seeking exposure to the future of financial systems.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is generating significant buzz and upward momentum, with the community actively celebrating notable price appreciation and continuous gains. Enthusiasts are rallying around an "unfolding prophecy" and "ETH season" narrative, firmly positioning $YEE as a compelling, generational meme coin to "study" and accumulate during market pullbacks.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to groundbreaking preliminary data from its FLAMINGO-01 trial, showing an impressive approximately 80% reduction in breast cancer recurrence rates, a development the community views as a significant de-risking event for the immunotherapy. This positive clinical update, coupled with an exceptionally high cost-to-borrow rate and a very low share float, is fueling intense investor speculation about an imminent short squeeze and potential strategic partnerships, as insiders continue to demonstrate strong conviction through share accumulation.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is a top trending stock following the landmark FDA approval of its oral Wegovy pill, a major development set to revolutionize the weight-loss market by offering a convenient, needle-free treatment option. The community is buzzing with optimism, anticipating significant long-term growth and market share expansion for NVO in the rapidly expanding GLP-1 sector, despite competitive dynamics.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending after federal regulators approved an emergency permit and granted interstate status for its Santa Ynez Pipeline System, shifting regulatory authority from California to federal oversight. This is widely seen as a game-changing event that could enable the company to finally move stored oil and potentially trigger a short squeeze. However, some investors remain cautious about possible state-level legal challenges or the potential for future equity offerings.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending after Sanofi's definitive agreement to acquire the company for $15.50 per share in cash, representing a significant premium. This move bolsters Sanofi's adult immunization portfolio with Dynavax's Heplisav-B and a promising shingles vaccine candidate. The community is actively debating the acquisition price, with many long-term shareholders expressing disappointment and some speculating on the possibility of a higher bid.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is seeing heightened conversation following a recent US$20 million public offering aimed at funding its demonstration-scale plant. Enthusiastic investors highlight the company's graduation from Shell's GameChanger program and new partnerships as strong validation for its unique recycling technology, while skeptics warn of a "pump and dump" lacking revenue and view the valuation as unsustainable.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following recent FDA approval of AQVESME for anemia in adults with alpha- or beta-thalassemia, marking it as the only approved therapy for this rare blood disorder. The community is expressing significant optimism, anticipating upward movement as this decision broadens the company's therapeutic offerings. This development is driving conversations around the stock's potential within the rare disease sector.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, a significant milestone for direct-to-device cellular broadband. While the news sparked initial excitement, it also led to some "sell the news" profit-taking, fueling a dynamic debate between long-term investors focused on the technology's massive potential and those anticipating short-term volatility. The community is actively discussing the company's future catalysts, viewing current dips as accumulation opportunities amidst projected billions in future revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$TRP Q3 earnings: In line but mixed results 📉

⚡️ Earnings of 56 cents/share matched estimates, driven by strong pipeline performance
📉 Revenue fell 10.1% YoY, impacted by weak Power &amp; Energy Solutions
📈 Mexico pipelines surged 57% in EBITDA, beating expectations

See the full analysis on TRP&#39;s performance and outlook 👉 https://www.zacks.com/stock/news/2788309/tc-energy-q3-earnings-match-estimates-revenues-beat-both-fall-yy?cid=sm-stocktwits-2-2788309-body-20251&amp;ADID=SYND_STOCKTWITS_TWEET_2_2788309_BODY_20251

Zacks

Pardon Our Interruption

Zacks Research

TC Energy Corporation

 Q3 earnings: In line but mixed results 📉

⚡️ Earnings of 56 cents/share matched estimates, driven by strong pipeline performance
📉 Revenue fell 10.1% YoY, impacted by weak Power & Energy Solutions
📈 Mexico pipelines surged 57% in EBITDA, beating expectations

See the full analysis on TRP's performance and outlook 👉 

This account is recognized as an Official Stocktwits Research Partner — working in close collaboration with Stocktwits to deliver in-depth research and market analysis.